CD44 Expression in Patients with Combined Hepatocellular Cholangiocarcinoma

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2015 Jul 2

PMID 26131439

Citations 11

Authors

Ryounggo Kim

Sang Bum Kim

Eung-Ho Cho

Sun Hoo Park

Sung Bae Park

Seong Kweon Hong

Gibong Chae

Affiliations

Soon will be listed here.

Abstract

Purpose: Combined hepatocellular cholangiocarcinoma (ChC) is a rare type of primary liver cancer, which is thought to have a poorer prognosis than hepatocellular carcinoma (HCC). Cancer stem cells are associated with tumorigenesis, tumor progression, recurrence, metastasis, and poor prognosis in several malignancies including HCC. The aim of this study was to investigate the expression pattern of cancer stem cell markers in ChC and HCC, and to evaluate whether this pattern correlated to patient prognosis.

Methods: Thirteen patients who underwent curative hepatic resection for ChC and 13 patients who underwent curative hepatic resection for HCC (matched control cases) were included. Immunohistochemical staining for cancer stem cell markers (cytokeratin [CK]7, CK19, C-kit, cluster of differentiation [CD] 44, CD133, and epithelial cell adhesion molecule) was performed and clinical outcomes were analyzed retrospectively.

Results: There was no significant difference in cancer stem cell marker expression between ChC and HCC. In ChC, the group that expressed CD44 showed earlier recurrence than the group that did not express CD44 (P = 0.040).

Conclusion: The expression of cancer stem cell markers in ChC did not show a different pattern compared to that found in HCC. The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.

Citing Articles

Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review.

Fakhrioliaei A, Tanhaei S, Pakmehr S, Shakir M, Qasim M, Hariri M J Membr Biol. 2024; 257(1-2):3-16.

PMID: 38356054 DOI: 10.1007/s00232-024-00307-2.

Deletion of Inhibits Metastasis Formation of Liver Cancer in -Mutant Mice.

Gerardo-Ramirez M, Giam V, Becker D, Groth M, Hartmann N, Morrison H Cells. 2023; 12(9).

PMID: 37174657 PMC: 10177437. DOI: 10.3390/cells12091257.

Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.

Rossner F, Sinn B, Horst D Cancers (Basel). 2023; 15(2).

PMID: 36672443 PMC: 9856551. DOI: 10.3390/cancers15020494.

A promising antitumor method: Targeting CSC with immune cells modified with CAR.

Huang B, Miao L, Liu J, Zhang J, Li Y Front Immunol. 2022; 13:937327.

PMID: 36032145 PMC: 9403009. DOI: 10.3389/fimmu.2022.937327.

A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.

Raevskaya O, Appelman H, Razumilava N Curr Hepatol Rep. 2021; 19(4):478-485.

PMID: 33415066 PMC: 7785105. DOI: 10.1007/s11901-020-00556-4.

References

Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R . New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res. 2010; 16(19):4688-94. PMC: 3395071. DOI: 10.1158/1078-0432.CCR-09-1811. View

Song W, Li H, Tao K, Li R, Song Z, Zhao Q . Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008; 62(8):1212-8. DOI: 10.1111/j.1742-1241.2008.01777.x. View

Lee J, Chung G, Yu S, Hwang S, Kim J, Kim H . Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol. 2010; 45(1):69-75. DOI: 10.1097/MCG.0b013e3181ce5dfa. View

Yu X, Xu L, Zeng H, Zhang R, Wang J, Liu C . Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2011; 10(6):620-5. DOI: 10.1016/s1499-3872(11)60105-7. View

Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M . Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2011; 19(5):1628-36. DOI: 10.1245/s10434-011-2150-0. View

Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M . A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996; 11(8):758-64. DOI: 10.1111/j.1440-1746.1996.tb00327.x. View

Cai X, Zhai J, Kaplan D, Zhang Y, Zhou L, Chen X . Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology. 2012; 56(5):1804-16. PMC: 4586114. DOI: 10.1002/hep.25874. View

Portolani N, Baiocchi G, Coniglio A, Piardi T, Grazioli L, Benetti A . Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol. 2008; 15(7):1880-90. DOI: 10.1245/s10434-008-9933-y. View

Komuta M, Spee B, Vander Borght S, De Vos R, Verslype C, Aerts R . Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008; 47(5):1544-56. DOI: 10.1002/hep.22238. View

10.

Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J . The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006; 49(2):138-51. DOI: 10.1111/j.1365-2559.2006.02468.x. View

11.

Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K . Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003; 33(6):283-7. DOI: 10.1093/jjco/hyg056. View

12.

Endo K, Terada T . Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol. 2000; 32(1):78-84. DOI: 10.1016/s0168-8278(00)80192-0. View

13.

Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M . Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013; 37(4):496-505. DOI: 10.1097/PAS.0b013e31827332b0. View

14.

Ikeda H, Harada K, Sato Y, Sasaki M, Yoneda N, Kitamura S . Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol. 2013; 140(3):329-40. DOI: 10.1309/AJCP66AVBANVNTQJ. View

15.

Yamashita T, Wang X . Cancer stem cells in the development of liver cancer. J Clin Invest. 2013; 123(5):1911-8. PMC: 3635728. DOI: 10.1172/JCI66024. View

16.

Lo R, Ng I . Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers. Liver Cancer. 2013; 2(2):84-92. PMC: 3740719. DOI: 10.1159/000343844. View

17.

Aruffo A, Stamenkovic I, Melnick M, Underhill C, Seed B . CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990; 61(7):1303-13. DOI: 10.1016/0092-8674(90)90694-a. View

18.

Yang X, Xu Y, Yu B, Zhou J, Qiu S, Shi G . High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59(7):953-62. DOI: 10.1136/gut.2008.176271. View

19.

Koh K, Lee H, Choi M, Lee J, Paik S, Yoo B . Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005; 189(1):120-5. DOI: 10.1016/j.amjsurg.2004.03.018. View

20.

Jarnagin W, Weber S, Tickoo S, Koea J, Obiekwe S, Fong Y . Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002; 94(7):2040-6. DOI: 10.1002/cncr.10392. View